Backs FY26 revenue view $1.3B-$1.31B, consensus $1.31B. Backs FY26 adjusted EBITDA view $555M-$565M. The company said, “HealthEquity (HQY) reaffirmed its previously provided outlook for the fiscal year that ended January 31, 2026, and the fiscal year ending January 31, 2027. The Company expects fiscal 2026 results to be near the top end of previously provided ranges. Based on the strong sales results reported today, the Company intends to provide updated full guidance for fiscal 2027 when it reports fiscal 2026 year-end results in March.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HQY:
- HealthEquity reports HSAs as of January 31 10.6M, up 7%
- HealthEquity price target lowered to $110 from $130 at BTIG
- HealthEquity price target lowered to $100 from $120 at Raymond James
- HealthEquity: Conservative Guidance, Custodial Yield Tailwinds, and Efficiency Gains Support Buy-Rated Upside
- HealthEquity Issues Confident Fiscal 2027 Outlook and Guidance